The CSPG4-specific monoclonal antibody enhances and prolongs the effects of the BRAF inhibitor in melanoma cells

Immunologic Research

Volumn 50, Issue 2-3, 2011, Pages 294-302

  Yu, Ling ^a,c   Favoino, Elvira ^b,c   Wang, Yangyang ^b,c   Ma, Yang ^c   Deng, Xiaojuan ^c   Wang, Xinhui ^a,c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

BRAF inhibitor PLX4032; BRAF inhibitor resistance; CSPG4 specific mAb; Melanoma; Signaling pathways

Indexed keywords

B RAF KINASE; CHONDROITIN SULFATE PROTEOGLYCAN 4; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 225.28; PROTEOGLYCAN; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; UNCLASSIFIED DRUG; VEMURAFENIB;

ARTICLE; CANCER INHIBITION; CELL ADHESION; CELL GROWTH; CELL MIGRATION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; DRUG ACTIVITY; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; CELL PROLIFERATION; CHONDROITIN SULFATE PROTEOGLYCANS; DOWN-REGULATION; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDOLES; MELANOMA; MEMBRANE PROTEINS; MUTATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; SIGNAL TRANSDUCTION; SULFONAMIDES;

EID: 79961167816     PISSN: 0257277X     EISSN: 15590755     Source Type: Journal    
DOI: 10.1007/s12026-011-8232-z     Document Type: Article

References (34)

1. RM MacKie A Hauschild AM Eggermont 2009 Epidemiology of invasive cutaneous melanoma Ann Oncol 20 Suppl 6 1 7
2. JS Cooper 2002 Radiation therapy of malignant melanoma Dermatol Clin 20 713 716 12380058 10.1016/S0733-8635(02)00029-3
3. N Cascinelli M Santinami A Maurichi R Patuzzo E Pennacchioli 2003 World Health Organization experience in the treatment of melanoma Surg Clin North Am 83 405 416 12744616 10.1016/S0039-6109(02)00089-0 (Pubitemid 36514816)
4. KT Flaherty I Puzanov KB Kim, et al. 2010 Inhibition of mutated, activated BRAF in metastatic melanoma N Engl J Med 363 809 819 20818844 10.1056/NEJMoa1002011 1:CAS:528:DC%2BC3cXhtVyksb3M
5. KT Flaherty G McArthur 2010 BRAF, a target in melanoma: implications for solid tumor drug development Cancer 116 4902 4913 20629085 10.1002/cncr.25261 1:CAS:528:DC%2BC3cXhsVymtL7L
6. L Gossage T Eisen 2010 Targeting multiple kinase pathways: a change in paradigm Clin Cancer Res 16 1973 1978 20215532 10.1158/1078-0432.CCR-09-3182 1:CAS:528:DC%2BC3cXktFygu7w%3D
7. KS Smalley KT Flaherty 2009 Integrating BRAF/MEK inhibitors into combination therapy for melanoma Br J Cancer 100 431 435 19156138 10.1038/sj.bjc.6604891 1:CAS:528:DC%2BD1MXhsFektr4%3D
8. C Montagut SV Sharma T Shioda, et al. 2008 Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma Cancer Res 68 4853 4861 18559533 10.1158/0008-5472.CAN-07-6787 1:CAS:528:DC%2BD1cXnt1ejsbs%3D
9. PA Janne N Gray J Settleman 2009 Factors underlying sensitivity of cancers to small-molecule kinase inhibitors Nat Rev Drug Discov 8 709 723 19629074 10.1038/nrd2871 1:CAS:528:DC%2BD1MXovFylur4%3D
10. PI Poulikakos C Zhang G Bollag KM Shokat N Rosen 2010 RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF Nature 464 427 430 20179705 10.1038/nature08902 1:CAS:528:DC%2BC3cXjsFWjsrs%3D
11. R Nazarian H Shi Q Wang, et al. 2010 Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation Nature 468 973 977 21107323 10.1038/nature09626 1:CAS:528:DC%2BC3cXhsVOrsbjI
12. CM Johannessen JS Boehm SY Kim, et al. 2010 COT drives resistance to RAF inhibition through MAP kinase pathway reactivation Nature 468 968 972 21107320 10.1038/nature09627 1:CAS:528:DC%2BC3cXhsVOrsLvP
13. M Campoli R Ferris S Ferrone X Wang 2010 Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies Clin Cancer Res 16 11 20 20028761 10.1158/1078-0432.CCR-09-2345 1:CAS:528:DC%2BC3cXotFyn
14. X Wang T Osada Y Wang, et al. 2010 CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer J Natl Cancer Inst 102 1496 1512 20852124 10.1093/jnci/djq343
15. X Wang Y Wang L Yu, et al. 2010 CSPG4 in cancer: multiple roles Curr Mol Med 10 419 429 20455858 10.2174/156652410791316977 1:CAS:528: DC%2BC3cXmsVamsbg%3D
16. J Yang MA Price CL Neudauer, et al. 2004 Melanoma chondroitin sulfate proteoglycan enhances FAK and ERK activation by distinct mechanisms J Cell Biol 165 881 891 15210734 10.1083/jcb.200403174 1:CAS:528:DC%2BD2cXltFKltbY%3D (Pubitemid 38821978)
17. J Yang MA Price GY Li, et al. 2009 Melanoma proteoglycan modifies gene expression to stimulate tumor cell motility, growth, and epithelial-to- mesenchymal transition Cancer Res 69 7538 7547 19738072 10.1158/0008-5472.CAN- 08-4626 1:CAS:528:DC%2BD1MXht1Skt7rK
18. W Bao S Stromblad 2004 Integrin alphav-mediated inactivation of p53 controls a MEK1-dependent melanoma cell survival pathway in three-dimensional collagen J Cell Biol 167 745 756 15557124 10.1083/jcb.200404018 1:CAS:528:DC%2BD2cXhtVaqtb3P (Pubitemid 39565154)
19. Schrama D, Keller G, Houben R, et al. BRAFV600E mutations in malignant melanoma are associated with increased expressions of BAALC. J Carcinog 2008;7:1.
20. Sondergaard JN, Nazarian R, Wang Q, et al. Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. J Transl Med 2010;8:39.
21. H Yang B Higgins K Kolinsky, et al. 2010 RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models Cancer Res 70 5518 5527 20551065 10.1158/0008-5472.CAN-10-0646 1:CAS:528:DC%2BC3cXot1Wks7Y%3D
22. KE O'Reilly M Warycha MA Davies, et al. 2009 Phosphorylated 4E-BP1 is associated with poor survival in melanoma Clin Cancer Res 15 2872 2878 19336517 10.1158/1078-0432.CCR-08-2336
23. C Domenzain-Reyna D Hernandez L Miquel-Serra, et al. 2009 Structure and regulation of the versican promoter: the versican promoter is regulated by AP-1 and TCF transcription factors in invasive human melanoma cells J Biol Chem 284 12306 12317 19269971 10.1074/jbc.M807108200 1:CAS:528:DC%2BD1MXltVClsr4%3D
24. G Bollag P Hirth J Tsai, et al. 2010 Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma Nature 467 596 599 20823850 10.1038/nature09454 1:CAS:528:DC%2BC3cXht1ajtbfK
25. MR Campoli CC Chang T Kageshita X Wang JB McCarthy S Ferrone 2004 Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance Crit Rev Immunol 24 267 296 15588226 10.1615/CritRevImmunol.v24.i4. 40 1:CAS:528:DC%2BD2MXotFOksw%3D%3D (Pubitemid 40052428)
26. F Perosa S Ferrone 1988 Syngeneic antiidiotypic monoclonal antibodies to the murine anti-HLA-DR, DP monoclonal antibody CR11-462 Hum Immunol 23 255 269 3266207 10.1016/0198-8859(88)90061-4 1:STN:280:DyaL1M7nsVSmsQ%3D%3D (Pubitemid 19009573)
27. M Temponi T Kageshita F Perosa R Ono H Okada S Ferrone 1989 Purification of murine IgG monoclonal antibodies by precipitation with caprylic acid: comparison with other methods of purification Hybridoma 8 85 95 2784406 10.1089/hyb.1989.8.85 1:CAS:528:DyaL1MXhvFSmt7o%3D (Pubitemid 19082761)
28. MA Burg A Nishiyama WB Stallcup 1997 A central segment of the NG2 proteoglycan is critical for the ability of glioma cells to bind and migrate toward type VI collagen Exp Cell Res 235 254 264 9281375 10.1006/excr.1997.3674 1:CAS:528:DyaK2sXlvVKgtLs%3D (Pubitemid 27381704)
29. MA Burg KA Grako WB Stallcup 1998 Expression of the NG2 proteoglycan enhances the growth and metastatic properties of melanoma cells J Cell Physiol 177 299 312 9766527 10.1002/(SICI)1097-4652(199811)177:2<299::AID-JCP12>3. 0.CO;2-5 1:CAS:528:DyaK1cXmsValt70%3D (Pubitemid 28452831)
30. KH Paraiso IV Fedorenko LP Cantini, et al. 2010 Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy Br J Cancer 102 1724 1730 20531415 10.1038/sj.bjc.6605714 1:CAS:528:DC%2BC3cXntFSnsrc%3D
31. R Halaban W Zhang A Bacchiocchi, et al. 2010 PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells Pigment Cell Melanoma Res 23 190 200 20149136 10.1111/j.1755-148X.2010.00685.x 1:CAS:528:DC%2BC3cXltF2ls7s%3D
32. J Villanueva A Vultur JT Lee, et al. 2010 Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3 K Cancer Cell 18 683 695 21156289 10.1016/j.ccr.2010.11.023 1:CAS:528:DC%2BC3cXhsFGhsbjJ
33. Flaherty K. 2011 [cited; Available from: http://www.dfhcc.harvard.edu/ news/news/article/4126/334/?PHPSESSID=c84186b744715f955d507b9356d0f3b2.
34. A Mittelman ZJ Chen H Yang GY Wong S Ferrone 1992 Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma Proc Natl Acad Sci USA 89 466 470 1731316 10.1073/pnas.89.2.466 1:STN:280:DyaK387hsFKrsQ%3D%3D